Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Nov 15;77(20):1801-7.
doi: 10.1212/WNL.0b013e318237f649. Epub 2011 Oct 19.

Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease)

J M Kwon  1 , H Adams, P G Rothberg, E F Augustine, F J Marshall, E A Deblieck, A Vierhile, C A Beck, N J Newhouse, J Cialone, E Levy, D Ramirez-Montealegre, L S Dure, K R Rose, J W Mink
Affiliations

Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease)

J M Kwon et al. Neurology. .

Abstract

Objective: To use the Unified Batten Disease Rating Scale (UBDRS) to measure the rate of decline in physical and functional capability domains in patients with juvenile neuronal ceroid lipofuscinosis (JNCL) or Batten disease, a neurodegenerative lysosomal storage disorder. We have evaluated the UBDRS in subjects with JNCL since 2002; during that time, the scale has been refined to improve reliability and validity. Now that therapies are being proposed to prevent, slow, or reverse the course of JNCL, the UBDRS will play an important role in quantitatively assessing clinical outcomes in research trials.

Methods: We administered the UBDRS to 82 subjects with JNCL genetically confirmed by CLN3 mutational analysis. Forty-four subjects were seen for more than one annual visit. From these data, the rate of physical impairment over time was quantified using multivariate linear regression and repeated-measures analysis.

Results: The UBDRS Physical Impairment subscale shows worsening over time that proceeds at a quantifiable linear rate in the years following initial onset of clinical symptoms. This deterioration correlates with functional capability and is not influenced by CLN3 genotype.

Conclusion: The UBDRS is a reliable and valid instrument that measures clinical progression in JNCL. Our data support the use of the UBDRS to quantify the rate of progression of physical impairment in subjects with JNCL in clinical trials.

PubMed Disclaimer

Figures

Figure
Figure. Physical Impairment domain scores worsen over time
(A) Physical Impairment scores at the most recent time of testing for all subjects are shown. The fitted line of predicted values (green dashed line) is based on ordinary linear regression analysis for the entire cohort using the most recent Physical Impairment score with age as the only independent variable. The colored labels indicate the subject's CLN3 genotype (CLN3 deletion homozygotes, filled blue diamond, and other CLN3 genotypes, filled red circle). Subject A is described in the text. (B) Physical Impairment scores of the subset who are homozygous for the common CLN3 deletion (the most common genotype seen). When subjects participated for multiple evaluations, their scores are marked by connected hollow blue diamonds. Those seen for a single visit are marked by a filled blue diamond. The fitted regression line (blue) with 95% confidence interval (CI) reflects the regression estimates for this subset only. The dashed green line is included to show the fitted regression for the entire cohort, discussed in A. (C) Physical Impairment scores of those with other CLN3 genotypes (noncommon deletion homozygotes.) When subjects participated for multiple evaluations, their scores are marked by connected hollow red circles, and those seen for a single visit are marked with a filled red circle. The fitted regression line with 95% CI reflects the regression estimates for this subset only. Subject A is described in the text.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Goebel HH, Wisniewski KE. Current state of clinical and morphological features in human NCL. Brain Pathol 2004; 14: 61–69 - PMC - PubMed
    1. Boustany RM. Neurology of the neuronal ceroid- lipofuscinoses: late infantile and juvenile types. Am J Med Genet 1992; 42: 533–535 - PubMed
    1. Consortium TIBD. Isolation of a novel gene underlying Batten disease, CLN3. Cell 1995; 82: 949–957 - PubMed
    1. Mitchison HM, Munroe PB, O'Rawe AM, et al. Genomic structure and complete nucleotide sequence of the Batten disease gene, CLN3. Genomics 1997; 40: 346–350 - PubMed
    1. Phillips SN, Benedict JW, Weimer JM, Pearce DA. CLN3, the protein associated with Batten disease: structure, function and localization. J Neurosci Res 2005; 79: 573–583 - PubMed

Publication types

MeSH terms